176 related articles for article (PubMed ID: 34181506)
1. Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries.
Gillard P; Povey M; Carryn S
Hum Vaccin Immunother; 2021 Oct; 17(10):3747-3756. PubMed ID: 34181506
[TBL] [Abstract][Full Text] [Related]
2. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
[TBL] [Abstract][Full Text] [Related]
3. Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants.
Habib MA; Prymula R; Carryn S; Esposito S; Henry O; Ravault S; Usonis V; Wysocki J; Gillard P; Povey M
Vaccine; 2021 Jun; 39(25):3445-3454. PubMed ID: 33736915
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
[TBL] [Abstract][Full Text] [Related]
5. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P
Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children.
Namazova-Baranova L; Habib MA; Povey M; Efendieva K; Fedorova O; Fedoseenko M; Ivleva T; Kovshirina Y; Levina J; Lyamin A; Ogorodova L; Reshetko O; Romanenko V; Ryzhenkova I; Sidorenko I; Yakovlev Y; Zhestkov A; Tatochenko V; Scherbakov M; Shpeer EL; Casabona G;
Hum Vaccin Immunother; 2022 Jan; 18(1):1959148. PubMed ID: 34435933
[TBL] [Abstract][Full Text] [Related]
8. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
9. One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life.
Henry O; Brzostek J; Czajka H; Leviniene G; Reshetko O; Gasparini R; Pazdiora P; Plesca D; Desole MG; Kevalas R; Gabutti G; Povey M; Innis B
Vaccine; 2018 Jan; 36(3):381-387. PubMed ID: 29224964
[TBL] [Abstract][Full Text] [Related]
10. Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?
Llenas-García J; Rubio R; Hernando A; Arrazola P; Pulido F
AIDS Care; 2013 Aug; 25(8):980-9. PubMed ID: 23244745
[TBL] [Abstract][Full Text] [Related]
11. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
[TBL] [Abstract][Full Text] [Related]
12. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial.
Povey M; Henry O; Riise Bergsaker MA; Chlibek R; Esposito S; Flodmark CE; Gothefors L; Man S; Silfverdal SA; Štefkovičová M; Usonis V; Wysocki J; Gillard P; Prymula R
Lancet Infect Dis; 2019 Mar; 19(3):287-297. PubMed ID: 30765242
[TBL] [Abstract][Full Text] [Related]
13. Long -term persistence of antibodies against varicella in fully immunized healthcare workers: an Italian retrospective cohort study.
Bianchi FP; Tafuri S; Larocca AMV; Germinario CA; Stefanizzi P
BMC Infect Dis; 2021 May; 21(1):475. PubMed ID: 34034659
[TBL] [Abstract][Full Text] [Related]
14. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children.
Shinefield HR; Black SB; Staehle BO; Matthews H; Adelman T; Ensor K; Li S; Chan I; Heyse J; Waters M; Chan CY; Vessey SJ; Kaplan KM; Kuter BJ;
Pediatr Infect Dis J; 2002 Jun; 21(6):555-61. PubMed ID: 12182381
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
17. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
18. Combination measles, mumps, rubella and varicella vaccine.
Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
[TBL] [Abstract][Full Text] [Related]
19. Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany.
Wiese-Posselt M; Siedler A; Mankertz A; Sauerbrei A; Hengel H; Wichmann O; Poethko-Müller C
BMC Infect Dis; 2017 May; 17(1):356. PubMed ID: 28525973
[TBL] [Abstract][Full Text] [Related]
20. Serologic analysis of the IgG antibody response in children with varicella zoster virus wild-type infection and vaccination.
Jenke AC; Klein S; Baiker A; Wirth S; Sander M; Noelting C; Boecher O; Vizoso-Pinto MG
Pediatr Infect Dis J; 2012 Nov; 31(11):1148-52. PubMed ID: 22863912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
